Pre-Public Hempsana Moving Quickly in Cannabis Derivatives Market


Robin Lefferts

May 7th, 2021

News, Top Story


 

Widely hailed as Cannabis 2.0, the current phase of growth in the legal cannabis market is fueled by cannabis-derived products based on oils, distillates, and isolates. These extracts contain various active ingredients, or cannabinoids, like CBD, THC, and rare cannabinoids such as CBN, CBG and Delta-8 THC. You may have noticed the explosion of CBD products in health food, grocery, and even convenience stores. According to Grandview Research, the global CBD market was valued at $2.8 billion in 2020 and is expected to grow at a 21.2% CAGR over the next several years. It’s a vast opportunity in its infancy, and all of it depends on the extraction and processing of quality base ingredients from the cannabis plant.

Hempsana Inc. recognizes the opportunity and is moving quickly to become a major global player in the world of cannabis derivatives. The company has licenses and approvals in place both in Canada and in the European Union, an EU-GMP compliant extraction, production, and distribution facility, and several contracts already active. Helmed by a diverse and experienced executive team, Hempsana is poised to go public in the very near future and continues to expand its presence across the derivatives market.

Not Just CBD

After decades of effective prohibition on both the consumption of and research into the cannabis plant, the science of cannabis is starting to hit its stride. Over 100 cannabinoids have been identified, going far beyond the widely-known CBD and THC. There are many research studies and clinical trials of the potential benefits of cannabinoids, and scientists have identified a natural system in the human body that interacts with them called the endocannabinoid system. The US Food and Drug Administration went so far as to publish a brief encouraging and supporting cannabinoid research and drug development, a clear sign the science of cannabis has hit the mainstream.

How does all of this research and validation tie into Hempsana and its mission to be the most trusted name in cannabis derivatives? First, researchers and pharmaceutical companies certainly comprise a target market for Hempsana’s cannabinoid derivatives. They need something pure and clean to study, and Hempsana can provide. Second, the scientific momentum is fueling acceptance of the plant as a viable alternative to some more traditional products, widening Hempsana’s playing field. Perhaps most importantly, research has uncovered over 100 cannabinoids, each one with the potential to benefit people. Each of these compounds requires extraction and purification, giving Hempsana market opportunities far beyond the common CBD and THC array of products.

Click here to receive an investor presentation and corporate updates

To be clear, Hempsana is not ignoring CBD and THC but rather sees an opportunity to be an early mover with cannabinoids such as CBN and Delta-8 THC. In Hempsana’s native Canada, there are currently a couple of major players in the cannabis extraction world. Both MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) and The Valens Company (TSX: VLNS) (OTCQX: VLNCF) are mostly focused on THC and CBD extracts, and rightfully so. Hempsana firmly believes two things. One, the market growth and potential for the global THC and CBD products is very large and allows room for competitors. Two, there is tremendous value in developing lesser-known cannabinoid products.

Hempsana’s Story

Hempsana was founded in October 2018 in Toronto. The company received confirmation to extract CBD oil from industrial hemp in Hungary, EU in February 2019. This was quickly followed by a Health Canada Industrial Hemp License in August 2019, and the Health Canada Standard Processing License in May 2020 for its Canadian operations. Hempsana’s wholly owned 8,000 square foot EU GMP compliant facility located in Goderich, Canada, was fully completed and commissioned in Q4 2020, with commercial production launched in December 2020.

The Hungarian component is a key to future growth, providing entry into the lucrative EU market. The Canadian EU-GMP compliant facility was also built with international export capabilities in mind, as those requirements are generally considered the most stringent in the world. From a facility standpoint, the table was set in the first two years of Hempsana’s existence.

Since its inception, the company has executed a number of processing and offtake agreements, with current production of cannabinoid derivatives set for over 27,000 kg of biomass extraction.  Hempsana offers three basic types of ingredients: crude full-spectrum oil, full-spectrum high concentrate distillate, and active pharmaceutical ingredient (API) grade isolate. These ingredients form the foundation of products ranging from topical creams, to foods, to pharmaceutical drug candidates.

Hempsana sells ingredients wholesale to qualified buyers that formulate and manufacture their own products. The company also offers more comprehensive services that manage refinement, and include purification, remediation, and even formulation services to cannabis companies without those capabilities. Hempsana also offers white label services, partnering with clients to take products from the idea stage all the way to a ready-to-sell package.

What’s Next

Consider this all an introduction to a new player in the global cannabinoid derivatives market. Hempsana recently announced a business combination agreement that sets the stage for its near-term go-public event, which will introduce the company to new funding sources to help fuel its growth plans. Hempsana is currently in the process of partnering with national brands in Canada, EU, and Asia to create sales verticals in key growth areas including the health supplement, topical cream, vape, and edibles markets. It’s an exciting time for the people at Hempsana, and interested investors are encouraged to keep an eye on this space for further developments.

Click here to receive an investor presentation and corporate updates

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Robin Lefferts has been involved in the legal cannabis industry since 2012, sometimes as an active participant and always as an interested observer.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading